Repros Therapeut. >>>Neue Testosteronwerte im Kursverlauf? - 500 Beiträge pro Seite

[MrRipley]

Hier vollkommen unbekannt, unverständlich wie ich meine.
Der Biotechinvestor hat die Aktie auf dem Radar, ich auch seit geraumer Zeit. Grund war ein Absturz mit zweifacher Gapbildung auf unter 1 USD.
Heute haben wir die 1 USD im Visier. Die FDA möchte mehr Einzelheiten über Repros Oral-Medikament erfahren, welches gegen Unfruchtbarkeit bei Männern wirken soll durch Anhebung des Hormonspiegels. Auch die sonstige Pipeline ist gefüllt.










Ein paar Biotech-Experten unter Euch sollen sich das bitte mal genauer anschauen.

Repros heutige Meldung:

http://www.businesswire.com/portal/site/repros/template.NDM/…

Marktcap ca 10 Mio USD

http://www.zonagen.com/

[MrRipley]

Die Gründe für den Absturz der letzten Monate und die Niedrigkursphase:


Insolvenzgefahr bestand im August 2009

http://www.bloggingstocks.com/2009/08/17/cash-strapped-repro…


und...

Medikament in der Testphase hat Patienten geschädigt, dagegen läuft auch eine Sammelklage.

[Joe_Trader]

habe den stock schon mehrmals getradet.
sehe die möglichkeit da wir uns bis nächste woche wieder bei 1,39 $ befinden.Das Ding wird heute und nächste Woche in den USA gezockt

SK von gestern ist schon okay.Denke heute wird es im Pre-market über einen 1 $ gehen und in diesem Bereich auch eröffnen.

Viel Glück allen.

[Joe_Trader]

http://ih.advfn.com/p.php?pid=squote&cb=1264651777&symbol=rp…
alles was man benötigt

[Joe_Trader]

http://www.nna100.com/stock_ranking.php?sortby=8&rev=-1&mark…

[Joe_Trader]

http://ih.advfn.com/p.php?pid=nmona&cb=1264651778&article=41…

[moneyhouse]

Guten Tag



bin mal mit ner kleinen Posi hier rein ..
100 % Chance besteht immer ...

Der Markt wartet ab ... ich denke
wenn ein der Kaufdruck wächst, sehen wir hier bald
die 2 USD Marke ...
Interessanter Wert

Euer Tip heute ???

[Joe_Trader]

heftiges auf und ab

[moneyhouse]

Servus

Wo geht denn die Reise hier denn hin ???

Seit Monaten lese ich nicht all zu Gutes über diese Firma.
Probleme bei Medikamenten, evt. Konkurs, fnanziell angeschlagen etc

Warum notiert die Aktie dann noch bei knapp 1 USD ?????

Dann müssten wir doch längst tiefere Kurse sehen ..

Besteht die Möglichkeit auf einen Rebound ??

In USA wird über Abzocke der Anleger geredet, man sollte
lieber die Finger von dieser Aktie lassen ??!!

Meinungen !!!

Merci

[expert007]

Antwort auf Beitrag Nr.: 38.842.713 von moneyhouse am 29.01.10 15:03:44

rprx wird 10 usd erreichen...

[moneyhouse]

Was macht Dich da so sicher ????

Wir fallen nachbörslich auch schon wieder Richtung 0,8 USD !!

Ich sehe hier keinen richtigen Schwung nach oben

[expert007]

Antwort auf Beitrag Nr.: 38.868.254 von moneyhouse am 02.02.10 23:36:32

bald kommt wieder positive news und es explodiert...

[Jano57]

08.02.2010 12:33
Repros Submits Response to FDA Regarding Androxal® Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility

Response will be Elaborated upon during BIO/CEO Presentation

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA's Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state. The Company also provided a literature review supporting the Company's belief that administration of exogenous testosterone at doses resulting in morning testosterone levels within the normal range render a significant number of men oligospermic (sperm counts less than the generally accepted level of male fertility). The Company also submitted the final clinical study report investigating the fertility impact of Androxal compared to a topical testosterone in men previously treated with testosterone for hypogonadism. Previously, the Company noted that the FDA suggested it will respond to Repros' submission in a timely fashion following receipt of Repros' materials.

Repros will provide an in depth review of the outcome of the Type C meeting held with the FDA on January 25, 2010 during its BIO/CEO presentation today at 2:30 p.m. Eastern Standard Time. There will be a live video webcast of the event and subsequently archived for at least one month on the Company's website http://www.reprosrx.com under the "Events" heading on the home page. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time to ensure adequate time to download any software that may be necessary.

http://www.finanznachrichten.de/nachrichten-2010-02/16087260…

[jaguar1803]

Potentieller Ten-Bagger hier !! Bin bei 0,63 US-DOLLAR eingestiegen !! TOP-Chance !! good luck to all !!!

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.272.162 von jaguar1803 am 04.04.10 09:27:26

Potentieller Ten-Bagger hier

Du meinst du siehst dich hier als Potentieller Bagholder

Teures Toilettenpapier würde ich mal sagen


As of December 31, 2009, we had approximately $1.9 million in cash and cash equivalents and our accounts payable and accrued expenses were approximately $2.4 million. The amount of cash on hand is not sufficient to fund future clinical trials of Androxal®, complete all necessary activities relating to the suspension of our clinical trial program for Proellex®, pay our accounts payable and accrued expenses as well as our normal corporate overhead and expenses. Significant additional capital will be required for us to continue development of either of our product candidates. The failure to raise sufficient funds in the first half of 2010, may result in the filing of bankruptcy or dissolution of the Company.

[jaguar1803]

Antwort auf Beitrag Nr.: 39.272.244 von BrauchGeld am 04.04.10 10:35:34

TOTGESAGTE LEBEN LÄNGER !!!!!

[jaguar1803]

TOP-NEWS !!!!!

Repros Requests Lift of Clinical Hold on Proellex®
Date : 04/05/2010 @ 6:59AM
Source : Business Wire
Stock : Repros Therapeutics Inc. (RPRX)
Quote : 0.611 0.0 (0.00%) @ 5:01PM


Repros Requests Lift of Clinical Hold on Proellex®
Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity. Previously, on August 3, 2009, Repros unilaterally suspended its then-ongoing Proellex® studies.

In the minutes of the meeting provided on September 3, 2009, the FDA made the following comments (in italics below), each of which is followed by a brief description of the Company's response to those comments:

Information Needed to Resolve the Full Clinical Hold

Before the Full Clinical Hold can be removed, you will need to provide, at a minimum, the information requested below. After we have reviewed the requested information, we may find it necessary to request additional information to support removal of the Full Clinical Hold.

Provide follow-up clinical and laboratory information from all subjects treated with Proellex® who exhibited any laboratory changes indicative of liver injury. These data should show that the liver injury in these subjects has resolved or stabilized.

On March 10, 2010, the Company provided a safety closeout of the roughly six month follow-up of subjects that were previously exposed to Proellex®. All subjects in the follow-up safety database have now exhibited liver enzymes within the normal range. These include the seven subjects that previously experienced serious adverse events. Six were exposed to 50 mg (includes the two Hy’s law cases). The one subject that experienced a liver related SAE at 25 mg was from an earlier Phase II study, during which she received 50mg for a 2 week period.

Provide information regarding serum concentrations of Proellex® in (1) the subjects who had any laboratory evidence of liver injury and (2) subjects who did not exhibit any evidence of liver injury. These data must demonstrate that there is a serum concentration of Proellex® below which there was no laboratory evidence of liver toxicity (i.e., no increase in liver enzymes).

Although serum concentrations were not routinely obtained in the Phase III studies, a clear dose effect emerged. In addition to tracking SAE’s, the Company also tracked liver enzyme elevations that fell outside the normal range. A review of the excursions above the normal range is exhibited in the following figure. The Company believes a clear dose response is apparent. These findings are particularly relevant in light of the observation that the longest duration of exposures occurred in the 25 mg group as part of an extension study, in which 32 subjects were exposed to Proellex® for between 361-720 days. Another 18 subjects were exposed for between 181-360 days. There were three subjects that experienced adverse events associated with elevated liver enzymes. The most notable was the subject previously reported as an SAE. She was randomized to the 25 mg group in the double blind study but she was initially treated with 50 mg Proellex®. The two other subjects that exhibited elevated liver enzymes in the extension study had conditions that may have resulted in elevations separate from that associated with the 25 mg dose. One subject reached liver enzyme elevations of 1.3XULN before discontinuing from the study. The investigator noted the potential for gall stones contributing to the observation. Another subject exhibited elevations of 7.5XULN but she was assessed to be positive for hepatitis C exposure based on the presence of antibodies against the virus.

Provide information regarding the likely mechanism(s) for the Proellex®-induced liver injury and the processes/steps that will be implemented to minimize the risk of liver injury if the Full Clinical Hold is removed.

The Company believes the adverse liver toxicity is a result of dose and subject related events. The toxicity observed presents as a drug induced hepatitis-like reaction. Repros believes these events result from the formation of adducts favored at high concentrations of the drug or its primary metabolite. The Company also believes that there is a subset of individuals, on the order of 7% of the population, that are capable of mounting an immune response to these adducts. In order for the liver toxicity to present itself, both a high concentration of drug and individual sensitivity is required. Repros believes doses of Proellex® at 12.5 mg or less will provide a safe and efficacious treatment for both uterine fibroids and endometriosis.

After the items listed above have been satisfactorily addressed, you can propose a dosing regimen to investigate the efficacy of Proellex®, which will result in serum concentrations of Proellex® (based on the upper bound of the expected 95% confidence limit) that will provide a sufficient margin of safety below the concentrations of Proellex® that were associated with laboratory evidence of liver injury.

The Company believes the data obtained to date indicates a clear dose relationship when viewed from the perspective of liver injury. The Company further believes that the risk of liver injury can be avoided by use of lower doses while still retaining a significant amount of the benefit of the drug. A previous Phase II study yielded strong efficacy outcomes for both the 12.5 mg and 25 mg doses of Proellex®. Though there was a slight drop off in efficacy at the 12.5 mg dose, the difference in results as compared to the 25 mg dose did not reach statistical significance within the study. Though Repros believes that with careful titration serious adverse liver events associated with the 25 mg dose can be minimized, the marginal benefit over the lower 12.5 mg dose does not warrant the risk associated with the 25 mg dose given its close proximity to the 50 mg dose. Based on the efficacy and safety of the 12.5 mg dose exhibited to date, Repros believes a safe dose can be developed at 12 mg or lower. To that end Repros commissioned Dr. Lawrence Fleckenstein PharmD, University of Iowa, to model projected exposure to Proellex® at doses of 12.5 mg and lower to determine the safety margin that might be obtained as compared to the clearly toxic 50 mg dose. Dr. Fleckenstein used available data from several Repros pharmacokinetic studies of the 25 and 50 mg dose of Proellex® to prepare his model. Dr. Fleckenstein’s model predicts that the 95% confidence interval of the maximum circulating concentrations of Proellex® at doses of 12.5 mg or lower are outside the 95% confidence interval of the 50 mg dose and only slightly impinge on the 25 mg 95% confidence interval for maximum concentration.

In the original minutes, the FDA further commented that it believed it would be difficult for the Company to determine a dose that would be both safe and effective.

It is estimated that 200,000 to 300,000 hysterectomies are performed annually in the United States to treat uterine fibroids and endometriosis. Hysterectomies are considered routine procedures and, although estimates vary, roughly 1 in 1000 procedures result in death or 200-300 women die every year in an attempt to gain relief from these conditions. Repros believes low dose Proellex® therapy can provide for a safe alternative to surgery.

In the body of the Company’s request to lift the clinical hold Repros made the following statement:

“Repros requests a lift of the full clinical hold on the Company’s Proellex® program to conduct a single study to determine the potential for developing a “low dose” oral anti-progestin therapy based on telapristone acetate or Proellex®. The Company has prepared a draft of a protocol that it believes will provide guidance for future studies (ZP-203). Repros believes that both the dose and duration of the study will not impose undue risk to study participants but the potential benefit resulting from the development of a safe and effective oral treatment could be large. The Company will commit to refrain from conducting any additional human trials until the results from ZP-203 are reviewed with the FDA and a mutually acceptable action plan can be developed. The Company understands should an unacceptable safety signal emerge in this study or that the potential benefits at the lower doses do not suggest clinical benefit the program may be terminated due to an inadequate risk/benefit profile.”

The Company awaits the FDA’s determination.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to maintain its listing on the NASDAQ Capital Market, raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, successfully defend itself against the class action complaints, whether clinical trials of Proellex® may be resumed, whether any safe and effective dose for Proellex® can be determined, whether clinical studies of Androxal will be successful, whether the FDA will consider an indication for secondary hypogonadism for Androxal and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6234877&lang…


Bookmark With :

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.274.455 von jaguar1803 am 05.04.10 13:06:03

Lies vorher das was du hier reinkopierst

[jaguar1803]

Antwort auf Beitrag Nr.: 39.274.466 von BrauchGeld am 05.04.10 13:09:59

hast ein problem mit good news ?!?!

[jaguar1803]

Antwort auf Beitrag Nr.: 39.274.466 von BrauchGeld am 05.04.10 13:09:59

premarket 0.7 DOLLAR !

[jaguar1803]

ASK schon 0.8 !!! Bald 1 DOLLAR !!!

[BrauchGeld]

Das Repros versucht das Hold von der FDA los zuwerden ist doch keine Nachricht wert aber wir wissen was die damit erreichen wollen .

Mir fällt da was zu Repros ein SCAMMMMMMMMMMMMMM

[jaguar1803]

Antwort auf Beitrag Nr.: 39.274.582 von BrauchGeld am 05.04.10 13:57:00

die 1 vor dem komma kommt bald und damit sind die probleme mit der nasdaq auch mal geschichte......ich glaub an repros !

[jaguar1803]

Antwort auf Beitrag Nr.: 39.274.582 von BrauchGeld am 05.04.10 13:57:00

für einen scam hat die firma eine zu lange geschichte ....1987 !!!!!!

[jaguar1803]

pre-market + 21,11 % auf 0.74 !

[jaguar1803]

Antwort auf Beitrag Nr.: 39.274.602 von jaguar1803 am 05.04.10 14:02:03

pre-market +30,89 % auf 0.80 !! Bis später...bin gespannt auf Kurs um 15:30 ! so long !!

[Lucky72]

[MrRipley]

Antwort auf Beitrag Nr.: 39.275.331 von Lucky72 am 05.04.10 17:43:59

jetzt kanns hochgehen

[Lucky72]

Viel sind aber nicht short!

http://www.shortsqueeze.com/?symbol=RPRX&submit=Short+Quote%…

[BrauchGeld]

Man nennt sowas auch "Dead Cat Bounce" ....

[natnoel]

bin mit einer kleinen posi dabei

[natnoel]

Antwort auf Beitrag Nr.: 39.434.494 von natnoel am 30.04.10 16:03:53

und wieder raus...kotz

[MrRipley]

Bodenbildung scheint beendet.

[JimmySpoon]

Antwort auf Beitrag Nr.: 40.031.462 von MrRipley am 23.08.10 19:45:42

Freitag rein zu 34 mit ner kleinen Posi !

Mal schaun was geht !!!

[Lucky72]

[MrRipley]

Antwort auf Beitrag Nr.: 40.031.699 von JimmySpoon am 23.08.10 20:21:13

Glückwunsch, ich war ne halbe Stunde Limits am optimieren in Frankfurt. Hätte mal besser über dem Ask zugegriffen

[ericcartman]

Oh ha doch ein paar Repros-Investierte , wurde übrigens auf "buy" hochgestuft mit KZ 1,50 $.

http://houston.bizjournals.com/houston/stories/2010/08/16/da…

[MrRipley]

Bisher 70% Kursplus.
Es gibt gute Nachrichten über das Testosteronmittel von der FDA - dem Mittel, weswegen ich diese Aktie für explosionsgefährdet halte. Was genau, habe ich noch nicht recherchiert.

[Gustl24]

Antwort auf Beitrag Nr.: 40.758.633 von MrRipley am 23.12.10 20:36:32

Repros Therapeutics (RPRX) Moves Higher On Androxal Data Submitted to FDA on Testosterone Levels


Repros Therapeutics Inc. (Nasdaq: RPRX) submitted to the FDA data collected from three different studies which its believes demonstrates that the assessment of testosterone levels between 8 and 10 in the morning is indicative of the maximum and average levels of the male hormone achieved during a particular day following the administration of Androxal®.

In the Type B meeting held on November 8, 2010, and reported in the Company’s press release of November 9, 2010, the FDA stated the preferred method to determine testosterone levels in treatments designed to replace the hormone is a 24 hour assessment.

Shares are moving higher on the news

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.114 von Gustl24 am 23.12.10 22:22:08

bin heute abend nach kurzem rücksetzer bei 2$ rein...

bei der geringen aktienanzahl könnte dies ein spannender kursverlauf werden...
weiss jemand die exakte zahl shares (stand heute) - im sommer ´10 kamen ca.
3 mio. dazu...ist das korrekt?

nach dem R/S aber noch immer extrem geringe zahl an shares - we will see

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.136 von Gustl24 am 23.12.10 22:29:34

vom kursverlauf sollte noch einiges möglich sein -
anzahl des heut gehandelten freefloats, MK, schluss auf TH und das börsenumfeld
mit highflyer Xoma...es ist angerichtet

der dünne handel über die feiertage als unbekannte variable

[expert007]

Antwort auf Beitrag Nr.: 40.759.144 von Gustl24 am 23.12.10 22:33:14

2,67 usd nachbörslich,ich habe auch gekauft...hofentlich gibts da noch luft nach oben...

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.487 von expert007 am 24.12.10 00:50:42

gibts...

börse ein spiel der gier und emotionen...nach dem run von XOMA die letzten tage
und den positiven news von repros gestern sollte da weit mehr gehen...

marktparameter passen...wenig shares, schluss auf tageshoch, nachbörslich up...

we will see

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.753 von Gustl24 am 24.12.10 09:12:21

wenn das volumen hoch genug ist die nächsten tage sehe ich kurse
von 4-5$ als durchaus realistisch...

wir werden sehen...ruhig und entspannt...wie es sich für die stade zeit gehört!

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.777 von Gustl24 am 24.12.10 09:24:45

eine schöne weihnachtszeit allen...handel wieder nächste woche in usa!!

[Gustl24]

Antwort auf Beitrag Nr.: 40.759.838 von Gustl24 am 24.12.10 09:54:40

zur info:

Repros shares skyrocket on drug news
Houston Business Journal - by Greg Barr
Date: Thursday, December 23, 2010

Shares of Repros Therapeutics Inc. nearly doubled in value Thursday in heavy volume after the company reported positive developments for its experimental testosterone deficiency drug, Androxal.
Repros (NASDAQ: RPRX) said in a statement that it had sent additional data to the U.S. Food and Drug Administration showing that a single assessment of testosterone levels collected in the morning correlates to maximum and average levels of testosterone during a 24-hour period in subjects taking Androxal.

The news sent the shares of The Woodlands-based company skyrocketing to a high of $2.60, before ending Thursday's trading at $2.57, a gain of $1.16 or 82 percent from the Dec. 22 close of $1.41. More than 7.5 million of the company's 8.9 million outstanding shares changed hands during Thursday's session.

so jetzt ist aber gut mit börse - schöne festtage

wünscht
Gustl

[MrRipley]

F*** ist das gut.
Nur Mist, dass ich nicht dabei bin.
Herzlichen Glückwunsch an alle Investierten!

[EvertonFC]

Antwort auf Beitrag Nr.: 41.135.145 von MrRipley am 02.03.11 18:02:51

Schade, dass hier nicht noch mehr User investiert sind

Repros hat unglaubliches Potential und ist ein gutes Beispiel dafür wie ineffizient Wall Street ist.

Nach dem damaligen Reverse Split sind Aktionäre in der traumhaften Lage trotz jüngster Kapitalerhöhung nur 15,5 Mio Aktien fully diluted vorzufinden. Der Float liegt nur bei gut 10 Mio Aktien. Die Aktie war eine Zeit lang zu 2,50 USD zu haben und erscheint auch bei 6,50 USD nicht besonders teuer.

Repros hat zwei Blockbuster in der Entwicklung für die es bisher keine alternativen Behandlungsmöglichkeiten gibt. Dem Testostoron-Medikament Androxal wird 1 Mrd. Marktpotential und dem Medikament Proellex 6 Mrd. Marktpotential zugebilligt. Man will 2012 beide Medikamente in Phase 3 haben. Die 2b-Phase für Androxal soll Ende 2011 abgeschlossen werden. Proellex hat jedoch den weit grösseren Markt.

Aktionäre müssen hier wie auch bei anderen Biotechs hoffen, dass die bisherigen Studienergebnisse bestätigt werden. Die Bewertungsrelation bei Repros ist trotzdem auffallend.

[ElfenbeinelaufenschnellermitKo]

Was ging ab heute, bin noch nicht ganz im Bilde.

[Nobert]

heute ist ein guter Tag für alle Repros Aktionäre!

Mega NEWS:

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism

http://ir.reprosrx.com/releasedetail.cfm?ReleaseID=868068

Starkes Plus heute dabei dürfte noch wesentlich luft nach oben sein...

Wenn ich richtig erinner liegt die marktkapitalisierung bei 300-400 mio und allein androxal hat ein Potential von 1Mrd......

Verdoppelung sollte immernoch möglich sein? Bitte um Berichtigung wenn das jemand besser weiß.

Schöne Grüße

Nobert

[Pedrocito]

Antwort auf Beitrag Nr.: 47.631.150 von Nobert am 28.08.14 10:28:35

April 1, 2015
Repros Announces Acceptance for Filing of NDA

THE WOODLANDS, Texas, April 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the New Drug Application (NDA) for its enclomiphene citrate product candidate, formerly known as Androxal®, has been accepted by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review. This investigational product, which is the Company's lead product candidate, is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The Company is developing this product candidate for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. The Company's product candidate is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to possible approval of the NDA by the FDA and the timeline for such approval and potential benefits and uses of the label for the product candidate and its commercial potential. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including risks that the FDA will not complete review of the NDA by the PDUFA date, that the FDA may not ultimately approve the product candidate, the risk that the that any marketing approvals, if granted, may have significant limitations on use, that even if the NDA is approved, the Company may not be able to successfully commercialize the product candidate, risks relating to the Company's ability to protect its intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com.

CONTACT: Investor Relations:

Thomas Hoffmann

The Trout Group

[phone]

[e-mail]

company logo
Source: Repros Therapeutics Inc.

News Provided by Acquire Media

[geldspender]

Gibt es Neue Entwicklungen bei der Aktie, die kurswirkend sind?

[geldspender]

Ist hier niemand investiert, eine Aktie die sehr stark schwankt, was ist kurstreibend?

[Biohero]

Antwort auf Beitrag Nr.: 51.225.630 von geldspender am 02.12.15 18:47:36

Die Firma war schon immer schrott hab die in der vergangenheit ein paar mal geshortet jetzt aber scheint endgültig der Ofen aus zu sein nachdem die FDA ihr Produkt abgelehnt hat . Die FDA empfiehlt eine neue Phase 3 Studie das aber wird viel Zeit und Geld kosten was RPRX nicht hat .Selbst wenn sie überleben sollten mit weiteren KE´s das Produkt ist uninteressant weil kaum Markt potential .



Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
http://finance.yahoo.com/news/repros-therapeutics-receives-c…


In the letter, the FDA stated that, based on recent scientific developments, the design of enclomiphene Phase 3 studies is no longer adequate to demonstrate clinical benefit and recommended that Repros conduct an additional Phase 3 study or studies to support approval in the target population.

[lunatics]

RPRX startet gerade durch! Momentan bei +140%
...und das ist erst der Anfang.

Repros Therapeutics Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3

[lunatics]

Ich schätze mal mit zukünftigem Phase III Boost gehts richtung 20 USD

[lunatics]

+175%
nicht schlecht Herr Specht

[Edison09]

Ich Troll hätte die Aktie heute zu 1,25€ haben können habe aber zulange gezögert

[Growth2012]

Antwort auf Beitrag Nr.: 52.182.709 von lunatics am 13.04.16 19:50:41

RPRX startet gerade durch! Momentan bei +140%
...und das ist erst der Anfang.


sehe ich auch so, eine rechte enge Kiste, mit nur 24 Mio Anteile im freien Umlauf

-


...more to come

[Growth2012]

Antwort auf Beitrag Nr.: 52.186.819 von Growth2012 am 14.04.16 10:36:37

Anybody know any women with his particular problem?


"reduction in excessive menstrual bleeding" ...every fourth female on this planet for exmaple!!!!!!



.....

[Growth2012]

Pre-Market : 2.58 Up 0.33 (14.67%)

[Rinawat]

http://stocktwits.com/symbol/RPRX

[larsuwe]

Bin auch erst heute eingestiegen,mal schauen wie sich der Aktienkurs heute der Heimatbörse zeigen wird?.Gruß Lars

[Growth2012]

Antwort auf Beitrag Nr.: 52.188.883 von larsuwe am 14.04.16 14:16:33

Werde ich wahrscheinlich bereuen aber bin raus um die 3.50$ (2.85€) rum....

Weiterhin good trades!

[Rinawat]

Antwort auf Beitrag Nr.: 52.189.921 von Growth2012 am 14.04.16 15:54:36

bin auch raus, mein vk limit wurde erreicht. passt schon

[lunatics]

Bei erfolgreicher Phase III steht der Kurs über 20

[Ulfred]

Antwort auf Beitrag Nr.: 52.191.349 von lunatics am 14.04.16 18:22:32

Zitat von lunatics: Bei erfolgreicher Phase III steht der Kurs über 20

Wann ist mit deren Abschluss zu rechnen?

[lunatics]

Antwort auf Beitrag Nr.: 52.191.355 von Ulfred am 14.04.16 18:23:28

Das lässt sich nie genau sagen.
Aber je länger je besser.

[larsuwe]

Anfang Juni sollen die Testergebnisse bekannt gegeben werden !. Am 5Mai Q 1 Zahlen 2016 .Bei erfolgreichen Test würde der Aktienkurs noch mal ordentlich nach oben laufen.Mal schauen, wie sich der Aktienkurs heute an der Heimatbörse zeigen wird ?.Nach unten sollte die 2$ Dollarmarke halten nach oben wären die 3$ Dollarmarke der nächste Wiederstand.Ich denke hier ist Potenzial vorhanden!.Gruß Lars

[Growth2012]

Antwort auf Beitrag Nr.: 52.194.139 von larsuwe am 15.04.16 08:24:36

Hi Larsuwe, besten Dank für die fundierte Aussage ....

Habe sie nun (dementsprechend) bis ende Mai wieder auf der watchlist genommen.

[lunatics]

Ausbruch!

[Growth2012]

Repros steht mittlerweile wieder interessant da...(auch wenn sie heute kurzweilig wieder down sind)

3 Biotech Stocks to Have on Your Watch-List in October

https://finance.yahoo.com/news/3-biotech-stocks-watch-list-1…

[Growth2012]

Rebound time

https://finance.google.com/finance?q=NASDAQ%3ARPRX&ei=k0sTWs…

[suedama]

Antwort auf Beitrag Nr.: 52.214.812 von lunatics am 18.04.16 16:36:24

allergan

Na die haben sie sich aber günstig eingesammelt...Mist!
Bin raus hab alle 10000 Stück verkauft...Nullsummenspiel!

Danke FDA

[Delta-Trading]

Bin mir nicht sicher, ob das Ding schon durch ist. Es sind wieder zwei Instis eingestiegen - der Buyout Preis ist ja lächerlich.